title: A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis.
abstract: Zuclopenthixol acetate--a new injectable formulation with a duration of action of 2-3 days--was compared with conventional intramuscular and oral formulations of haloperidol and zuclopenthixol in the initial treatment of acutely disturbed, psychotic patients. The patients were stratified into 3 diagnostic categories: acute psychoses (48 patients), mania (22 patients), and exacerbation of chronic psychoses (73 patients). The patients were rated on the Brief Psychiatric Rating Scale (BPRS), the Bech-Rafaelsen Mania Rating Scale (BRMAS) (only manic patients) and globally on the Clinical Global Impression (CGI). The study was an open, randomized multicentre trial with a 6-day treatment period. The zuclopenthixol acetate patients received 1-4 doses, the haloperidol patients 1-26 and the zuclopenthixol patients 1-22 doses. The assessments on the CGI showed that all 3 treatments caused a clear reduction of the severity of illness scores in all 3 diagnostic categories, with no differences between treatments. The ratings of the acute and chronic psychotic patients on the BPRS also showed significant reductions in scores with no differences between treatments. All 3 treatments caused a rapid remission of symptoms on the BRMAS. Haloperidol induced hypokinesia in significantly more patients than zuclopenthixol acetate after 24 h. Later there were no significant differences between treatments. Zuclopenthixol acetate fulfils many desires for an amended neuroleptic formulation for the initial treatment of acutely disturbed psychotic patients.
authors.affiliation: KAS Nordvang, Glostrup, Denmark.
authors.forename: P C
authors.initials: PC
authors.lastname: Baastrup
authors.forename: U G
authors.initials: UG
authors.lastname: Alhfors
authors.forename: L
authors.initials: L
authors.lastname: Bjerkenstedt
authors.forename: S J
authors.initials: SJ
authors.lastname: Dencker
authors.forename: C
authors.initials: C
authors.lastname: Fensbo
authors.forename: A
authors.initials: A
authors.lastname: Gravem
authors.forename: V
authors.initials: V
authors.lastname: Pedersen
authors.forename: K
authors.initials: K
authors.lastname: Elgen
authors.forename: B
authors.initials: B
authors.lastname: Brekke
authors.forename: K
authors.initials: K
authors.lastname: Fredslund-Andersen
mesh_terms: D000208:Acute Disease; D000328:Adult; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003006:Clopenthixol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009821:Oils; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D009821:Oils; C060342:clopenthixol acetate ester; D003006:Clopenthixol; D006220:Haloperidol